Product Details


  • image description

Try Ortho•Heart

  • A Comprehensive Cardiovascular Formula
  • A synergistic herb and vitamin formula for healthy heart function
  • Supports healthy blood pressure and cholesterol levels
  • Improves oxygen delivery to the body
  • A unique formula from AOR

Use this product for:

Related products you may be interested in


Advanced Cardiac Support contains ingredients to help support overall cardiovascular health and provides antioxidants for the maintenance of good health.

Product Variations

NPN Product Code Size
80032442 AOR04211 60 V-CAPS

Supplement Facts

Amount Per Serving Amount: 2 Capsules
20 mg Olive Extract* (50:1)
Non-medicinal ingredients: maltodextrin, potato starch, silica. Capsule: hypromellose. *Typically 10% hydroxytyrosol. **Powergrape is a registered trademark of Naturex Inc.
420 mg Curcumin
400 mg Powergrape grape extract** (10-15:1)
90 mg Co-enzyme Q10
600 mg Terminalia arjuna extract (8-10:1)
50 mg Pyridoxal-5-Phosphate

AOR™ guarantees that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Suggested Use:

Take 1 capsule twice daily with/without food, or as directed by a qualified health care professional.

Cautions :

Consult a health care practitioner prior to use if you are taking blood pressure medication, antiplatelet medication, blood thinners or health products which may aggravate electrolyte imbalance, if you have a heart condition, gallstones, a bile duct obstruction, stomach ulcers, excess stomach acid, a kidney disorder, or if you are dehydrated. Consult a health care practitioner if symptoms persist or worsen, or for use beyond four weeks.

Pregnancy/Breastfeeding :

Do not take.



Main Applications:

  • Cardiovascular Support
  • Cholesterol Balance
  • Blood Pressure Balance
  • Physical Performance
  • Cardiac Hypertrophy

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

The cardiovascular system is composed of the heart and a complex network of blood vessels, including arteries, veins and capillaries. The main function of this system is to deliver oxygen and nutrients to the cells of the body, while taking away waste products. Any dysfunction in this critical system can lead to major health problems and even death.

Advanced Cardiac Support provides a medley of well-known nutrients with established reputations for maintaining a properly functioning cardiovascular system including curcumin from turmeric root, antioxidant co-enzyme Q10, the ayurvedic herb arjuna, vitamin B6, Powergrape® whole grape extract and olive extract containing the powerful antioxidant hydroxytyrosol. This formula blends the best heart-healthy nutrients from ancient and modern medicines from around the world to provide a well-rounded heart support product.

Advanced Cardiac Support from AOR includes superior ingredients for the support of heart health, and is suitable both for individuals looking to protect and maintain the health of their heart as well as for those who already suffer from cardiovascular problems.


Most people know that turmeric is a healthy spice. What most people don’t know is that its anti-inflammatory and anti-cancer benefits are mainly attributed to curcumin, one of its active components that makes up only about 2% of turmeric extract. What’s more, it’s not very well absorbed.


CoQ10 is becoming one of the main nutrients to have crossed over from natural health circles into western medical medicine, where it is being recognized as an important heart health factor. It is quite well known now that statin medications taken for high cholesterol often deplete the heart’s CoQ10 levels, putting patients at risk for other cardiovascular complications.


Terminalia arjuna is not a very well-known herb on the market, but it is well-studied in modern medicine to lend support in the most severe of cardiovascular diseases.

Vitamin B6

B-Vitamins tend to be known for general health, stress or improved energy. But B6 can do more!


Grapes are one of the most well-known heart healthy foods. Wine, in particular, accounts for much of the French paradox of high wine consumption and good heart health. In North America, grape seed extract is the most popular supplement form of grapes. But what about the rest of the grape? AOR takes the grape a step further with PowergrapeTM.


Olive oil is the most popular oil for heart health, with its benefits mainly being attributed to its monounsaturated fat content. The Mediterranean diet is high in olive oil consumption, and its partakers tend to suffer less heart disease. But olives contain other components that deserve recognition.

Advanced Cardiac Support combines science and knowledge from renowned traditions and medical systems around the world including Ayurvedic medicine, Mediterranean & French Culture, and Japanese & western medicine to form the most advanced heart health maintenance supplement. It features active, bioavailable and powerful ingredients while highlighting some of their under-appreciated health benefits.

Curcumin and the Heart

Curcumin possesses anti-inflammatory, anti-fungal, neuroprotective, metabolic and immune system enhancing properties in addition to its well-documented cardiovascular benefits. These benefits have been clinically demonstrated in studies examining the effect of curcumin supplementation on serum cholesterol and lipid peroxide levels in healthy human subjects. Results showed a 33% reduction in lipid peroxide levels along with a 29% increase in HDL cholesterol and a 12% reduction in total cholesterol.  Curcumin also inhibits and reverses cardiac hypertrophy, which often results from scar tissue formation in the cardiac muscle. Hypertrophy of the heart muscle predisposes to heart problems.

Co-Enzyme Q10: Unquestionably Effective

Since 1974, co-enzyme Q10 (CoQ10) has actually been approved as a drug in Japan – and later other nations – for the treatment of heart problems. Placebo-controlled studies with CoQ10 (including one conducted in Italy involving 2,664 patients with heart problems) have produced significantly positive results. In Canada, the evidence had become so compelling that the Natural Health Products Directorate went so far as to formally assign a monograph to CoQ10 in 2007, officially acknowledging the validity of its claims and attesting to its cardiovascular benefits. A recent large study found that CoQ10 reduced hospital stays and mortality in certain heart patients, and the authors recommended that CoQ10 be considered a staple maintenance prescription for heart patients.

Terminalia arjuna: Increasing the Flow

Like CoQ10, Terminalia arjuna has established a clinical presence in patients with cardiac problems. Unlike CoQ10, which operates at the mitochondrial level, the mechanism of action for Terminalia arjuna (or simply arjuna) is more directly concentrated around increasing cardiac muscle capacity. In a double-blind, placebo-controlled crossover study among patients with heart problems, arjuna supplementation was able to ameliorate symptoms to such a degree that all patients had their conditions reclassified. Furthermore, arjuna increased the blood-pumping activity of their hearts by 10% and the efficiency of those hearts at emptying blood out the left ventricle (ejection fraction) rose by nearly 20%. In the treatment of angina, studies have shown arjuna supplementation to be capable of reducing the frequency of attacks by two-thirds among stable angina patients. One study found that arjuna was as effective as isosorbide mononitrate (a common angina prevention medication) at reducing angina attacks and improving exercise capacity; patients also needed less isosorbide mononitrate when taking arjuna. Clinical trials have also been performed with heart patients – with encouraging results.

Vitamin B6: Reduces Homocysteine

A deficiency in vitamin B6 can lead to elevated homocysteine levels. Homocysteine is a toxic amino acid that is a byproduct of certain metabolic pathways in the body. High levels of this amino acid have been associated with higher incidences of coronary artery disease and increased risk of mortality from cardiovascular diseases. The conversion of homocysteine into less toxic alternatives requires the presence of vitamin B6. Supplementing with this important vitamin can help keep homocysteine levels in check, thereby helping to reduce cardiovascular disease risk. Vitamin B6 also acts to reduce inflammation. Pyridoxal-5’-phospate is a superior, active form of vitamin B6.

Grape Extract: Heart Protector

PowergrapeTM is a potent whole grape extract rich in antioxidant compounds including polyphenols, flavanols and flavanol monomers. This powerful grape extract has been clinically demonstrated to reduce oxidative stress, improve physical performance, protect the muscles from damage and to improve oxygen delivery to the cells of the body. Grape extracts have also been studied extensively for their benefits to cardiovascular health, including their ability to reduce the oxidation of LDL cholesterol.

Hydroxytyrosol: The most Powerful Antioxidant

Hydroxytyrosol is a compound present in olives. Hydroxytyrosol has the distinction of having the highest radical scavenging ability ever reported for any natural antioxidant compound. It is thought that this compound may play a key role in the better health and reduced incidence of cardiovascular disease in people eating a “Mediterranean diet”. Hyrdoxytyrosol has been shown to strongly inhibit peroxidation of LDL cholesterol, a key factor in the development of atherosclerosis. In one study involving 40 men with coronary heart disease daily consumption of raw virgin olive oil was associated with better antioxidant status, reduction in oxidized LDL and lower systolic blood pressure.

The effect of coenzyme Q10 on morbidity and mortality in chronicheart problems. Results from the Q-SYMBIO study.

European Journal ofheart problems ( 2013 ) 15 ( S1 ), S20

Mortensen SA, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP, Rosenfeldt F.

Dysfunction of bioenergetics and energy starvation of the myocardium may be a dominant feature of heart problems (HF) and attention is directed towards a support of the myocardial metabolism. The myocardial tissue level of the essential redox component of the respiratory chain Coenzyme Q10 (CoQ10) has been found inversely related to the severity of HF. We investigated the effects of CoQ10 on patients symptoms, functional capacity and biomarker status (NT-proBNP) and the long-term outcome with morbidity and mortality.

Methods: HF patients in New York Heart Association (NYHA) Class III or IV who were receiving current pharmacologic therapy were randomly assigned in parallel groups to CoQ10 100 mg three times daily versus placebo. The primary long-term endpoint was the time to first MACE (major adverse cardiovascular event) including unplanned hospitalization due to worsening of HF, cardiovascular death, urgent cardiac transplantation and mechanical support, using a time to first event analysis.

Results: A total of 420 patients – CoQ10 (N=202), placebo (N=218) – were enrolled with a follow-up time of 2 years. After 3 months there was a trend with a reduced level of NT-proBNP in the CoQ10 group. After 2 years there was a significant improvement of the NYHA Class in the CoQ10 group (p=0.047). The primary endpoint was reached by 29 patients in the CoQ10 group, as compared with 55 patients in the placebo group (14 percent vs. 25 percent; hazard ratio CoQ10 vs. placebo: 2.0 (95% CI: 1.3-3.2); P=0.003) by intention to treat analysis. CoQ10 treated patients had significantly lower cardiovascular mortality (p=0.02) and lower occurrence of hospitalizations for HF (p=0.05). All cause mortality was also lower in the CoQ10 group, 18 patients vs. 36 patients in the placebo-group (9 percent vs. 17 percent; hazard ratio CoQ10 vs. placebo: 2.1 (95% CI: 1.2-3.8); p=0.01). There were fewer adverse events in the CoQ10 group compared to the placebo group (p=0.073).

Conclusions: Q-SYMBIO is the first double-blind trial in chronic HF addressing whether CoQ10 supplementation might improve survival. The CoQ10 treated patients had reduced hospital admission rates for worsening HF and lower cardiovascular death both of which may reflect a significant improvement in cardiac function. CoQ10 treatment was safe with a reduced all cause mortality rate. CoQ10 should be considered as a part of the maintenance therapy of patients with chronic heart problems.


Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women.

Nutr Res. 2012 Oct;32(10):795-9.

Akazawa N, Choi Y, Miyaki A, Tanabe Y, Sugawara J, Ajisaka R, Maeda S.

Vascular endothelial function is declines with aging and is associated with an increased risk of cardiovascular disease. Lifestyle modification, particularly aerobic exercise and dietary adjustment, has a favorable effect on vascular aging. Curcumin is a major component of turmeric with known anti-inflammatory and anti-oxidative effects. We investigated the effects of curcumin ingestion and aerobic exercise training on flow-mediated dilation as an indicator endothelial function in postmenopausal women. A total of 32 postmenopausal women were assigned to 3 groups: control, exercise, and curcumin groups. The curcumin group ingested curcumin orally for 8 weeks. The exercise group underwent moderate aerobic exercise training for 8 weeks. Before and after each intervention, flow-mediated dilation was measured. No difference in baseline flow-mediated dilation or other key dependent variables were detected among the groups. Flow-mediated dilation increased significantly and equally in the curcumin and exercise groups, whereas no changes were observed in the control group. Our results indicated that curcumin ingestion and aerobic exercise training can increase flow-mediated dilation in postmenopausal women, suggesting that both can potentially improve the age-related decline in endothelial function.


Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women.

The American Journal of Clinical Nutrition. 2007; 85(3): 895-909.

Mink PJ et al.

Background: Dietary flavonoids may have beneficial cardiovascular effects in human populations, but epidemiologic study resultshave not been conclusive.

Objective: We used flavonoid food composition data from 3 recentlyavailable US Department of Agriculture databases to improveestimates of dietary flavonoid intake and to evaluate the associationbetween flavonoid intake and cardiovascular disease (CVD) mortality.

Design: Study participants were 34 489 postmenopausal women in the Iowa Women’s Health Study who were free of CVD and had complete food-frequency questionnaire information at baseline. Intakes of total flavonoids and 7 subclasses were categorized into quintiles, and food sources were grouped into frequency categories. Proportional hazards rate ratios (RR) were computed for CVD, coronary heart disease (CHD), stroke, and total mortality after 16 y of follow-up.

Results: After multivariate adjustment, significant inverse associations were observed between anthocyanidins and CHD, CVD, and total mortality [RR (95% CI) for any versus no intake: 0.88(0.78, 0.99), 0.91 (0.83, 0.99), and 0.90 (0.86, 0.95)]; between flavanones and CHD [RR for highest quintile versus lowest: 0.78(0.65, 0.94)]; and between flavones and total mortality [RRfor highest quintile versus lowest: 0.88 (0.82, 0.96)]. No association was found between flavonoid intake and stroke mortality. Individual flavonoid-rich foods associated with significant mortality reduction included bran (added to foods; associated with stroke and CVD);apples or pears or both and red wine (associated with CHD andCVD); grapefruit (associated with CHD); strawberries (associated with CVD); and chocolate (associated with CVD).

Conclusion: Dietary intakes of flavanones, anthocyanidins, and certain foods rich in flavonoids were associated with reduced risk of death due to CHD, CVD, and all causes.


Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial.

Atherosclerosis. 2005; 181(1): 149-158.

Fito M et al.

The Mediterranean diet, in which olive oil is the main source of fat, has been associated with a reduced incidence of coronary heart disease (CHD) and low blood pressure levels. Virgin olive oil (VOO), besides containing monounsaturated fat, is rich in phenolic compounds (PC) with antioxidant properties. The aim of this study was to examine the antioxidant and anti-hypertensive effect of two similar olive oils, but with differences in their PC (refined: 14.7 mg/kg versus virgin: 161.0 mg/kg), in 40 males with stable CHD. The study was a placebo controlled, crossover, randomized trial. A raw daily dose of 50 mL of VOO and refined olive oil (ROO) were sequentially administered over two periods of 3 weeks, preceded by 2-week washout periods in which ROO was used. Lower plasma oxidized LDL (p < 0.001) and lipid peroxide levels (p = 0.003), together with higher activities of glutathione peroxidase (p = 0.033), were observed after VOO intervention. Systolic blood pressure decreased after intake of VOO (p = 0.001) in hypertensive patients. No changes were observed in diastolic blood pressure, glucose, lipids, and antibodies against oxidized LDL. Consumption of VOO, rich in PC, could provide beneficial effects in CHD patients as an additional and complementary intervention to the pharmacological treatment.


Curcumin as “Curecumin”: from kitchen to clinic.

Goel A, Kunnumakkara AB, Aggarwal BB.

Biochem Pharmacol; 2005, 75(4):787-809

Although turmeric (Curcuma longa; an Indian spice) has been described in Ayurveda, as a treatment for inflammatory diseases and is referred by different names in different cultures, the active principle called curcumin or diferuloylmethane, a yellow pigment present in turmeric (curry powder) has been shown to exhibit numerous activities. Extensive research over the last half century has revealed several important functions of curcumin. It binds to a variety of proteins and inhibits the activity of various kinases. By modulating the activation of various transcription factors, curcumin regulates the expression of inflammatory enzymes, cytokines, adhesion molecules, and cell survival proteins. Curcumin also downregulates cyclin D1, cyclin E and MDM2; and upregulates p21, p27, and p53. Various preclinical cell culture and animal studies suggest that curcumin has potential as an antiproliferative, anti-invasive, and antiangiogenic agent; as a mediator of chemoresistance and radioresistance; as a chemopreventive agent; and as a therapeutic agent in wound healing, diabetes, Alzheimer disease, Parkinson disease, cardiovascular disease, pulmonary disease, and arthritis. Pilot phase I clinical trials have shown curcumin to be safe even when consumed at a daily dose of 12g for 3 months. Other clinical trials suggest a potential therapeutic role for curcumin in diseases such as familial adenomatous polyposis, inflammatory bowel disease, ulcerative colitis, colon cancer, pancreatic cancer, hypercholesteremia, atherosclerosis, pancreatitis, psoriasis, chronic anterior uveitis and arthritis. Thus, curcumin, a spice once relegated to the kitchen shelf, has moved into the clinic and may prove to be “Curecumin”.


Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate.

Indian Heart J. 2002 Mar-Apr;54(2):170-5.

Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG.

BACKGROUND: Terminalia arjuna, an Indian medicinal plant, has been reported to have beneficial effects in patients with ischemic heart disease in a number of small, open studies. The need for a double-blind, randomized, placebo-controlled study with adequate sample size has long been felt. The bark extract (IPC-53) contains acids (arjunic acid, terminic acid), glycosides (arjunetin arjunosides I-IV), strong antioxidants (flavones, tannins, oligomeric proanthocyanidins), minerals. etc. and exhibits antifailure and anti-ischemic properties.

METHODS AND RESULTS: Fifty-eight males with chronic stable angina (NYHA class II-III) with evidence of provocable ischemia on treadmill exercise test received Terminalia arjuna (500 mg 8 hourly), isosorbide mononitrate (40 mg/daily) or a matching placebo for one week each, separated by a wash-out period of at least three days in a randomized, double-blind, crossover design. They underwent clinical, biochemical and treadmill exercise evaluation at the end of each therapy which were compared during the three therapy periods. Terminalia arjuna therapy was associated with significant decrease in the frequency of angina and need for isosorbide dinitrate (5.69 /-6.91 mg/week v. 18.22 /-9.29 mg/week during placebo therapy, p<0.005). The treadmill exercise test parameters improved significantly during therapy with Terminalia arjuna compared to those with placebo. The total duration of exercise increased (6.14 /-2.51 min v. 4.76 /-2.38 min, p<0.005), maximal ST depression during the longest equivalent stages of submaximal exercise decreased (1.41 /-0.55 mm v. 2.21 /-0.56 mm, p<0.005), time to recovery decreased (6.49 /-2.37 min v. 9.27 /-3.39 min, p<0.005) and higher double products were achieved (25.75 /-4.81×10(3) v. 23.11 /-4.83×10(3), p<0.005) during Terminalia arjuna therapy. Similar improvements in clinical and treadmill exercise test parameters were observed with isosorbide mononitrate compared to placebo therapy. No significant differences were observed in clinical or treadmill exercise test parameters when Terminalia arjuna and isosorbide mononitrate therapies were compared. No significant untoward effects were reported during Terminalia arjuna therapy.

CONCLUSIONS: Terminalia arjuna bark extract, 500 mg 8 hourly, given to patients with stable angina with provocable ischemia on treadmill exercise, led to improvement in clinical and treadmill exercise parameters as compared to placebo therapy. These benefits were similar to those observed with isosorbide mononitrate (40 mg/day) therapy and the extract was well tolerated. Limitations of this study include applicability of the results to only men with chronic stable angina but not necessarily to women, as they were not studied.


Effect of Hydroxytyrosol Found in Extra Virgin Olive Oil on Oxidative DNA Damage and on Low-Density Lipoprotein Oxidation.

J Agric. Food Chem. 1998; 46(12): 5181-5187.

Aruoma OI et al.

Hydroxytyrosol found in extra virgin olive oil strongly inhibited low-density lipoprotein oxidation stimulated by 2,2‘-azobis(2-amidinopropane) hydrochloride (AAPH), suggesting the ability to scavenge the AAPH-derived peroxyl radicals. Hydroxytyrosol inhibited iron-dependent phospholipid liposome peroxidation at low concentrations (IC50 = 50 ± 1.3 μM). In similar experiments, the calculated, IC50 values for other antioxidants compared are 1.5 ± 0.05 μM (carnosol), 2.25 ± 0.08 μM (carnosic acid), 65 ± 2.6 μM (Trolox C), and 250 ± 10 μM (vitamin E). Hydroxytyrosol and ascorbate reduced copper(II) ions to their copper(I) prooxidant form, but this was not reflected by their abilities to induce oxidative DNA damage in the complex copper−phenanthroline. Only high, nonphysiological, millimolar concentrations of pure hydroxytyrosol weakly stimulated copper-dependent chemical modification to DNA bases. The prooxidant (redox actions on metal ions) concentrations in vitro may never be achieved in vivo (following consumption of extra virgin olive oil). Thus, hydroxytyrosol may represent a useful diet-derived antioxidant depending on its bioavailability.


Salutary effect of Terminalia Arjuna in patients with severe refractoryheart problems.

Int J Cardiol. 1995 May;49(3):191-9.

Bharani A, Ganguly A, Bhargava KD.

Twelve patients with refractory chronic heart problems (Class IV NYHA), related to idiopathic dilated cardiomyopathy (10 patients); previous myocardial infarction (one patient) and peripartum cardiomyopathy (one patient), received Terminalia Arjuna, an Indian medicinal plant, as bark extract (500 mg 8-hourly) or matching placebo for 2 weeks each, separated by 2 weeks washout period, in a double blind cross over design as an adjuvent to maximally tolerable conventional therapy (Phase I). The clinical, laboratory and echocardiographic evaluation was carried out at baseline and at the end of Terminalia Arjuna and placebo therapy and results were compared. Terminalia Arjuna, compared to placebo, was associated with improvement in symptoms and signs of heart problems, improvement in NYHA Class (Class III vs. Class IV), decrease in echo-left ventricular enddiastolic (125.28 /- 27.91 vs. 134.56 /- 29.71 ml/m2; P < 0.005) and endsystolic volume (81.06 /- 24.60 vs. 94.10 /- 26.42 ml/m2; P < 0.005) indices, increase in left ventricular stroke volume index (44.21 /- 11.92 vs. 40.45 /- 11.56 ml/m2; P < 0.05) and increase in left ventricular ejection fractions (35.33 /- 7.85 vs. 30.24 /- 7.13%; P < 0.005). On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life.


Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart problems.

Mol Aspects Med; 1994, 15 Suppl:s287-94

CoQ10 Drug Surveillance Investigators. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G.

Digitalis, diuretics and vasodilators are considered the standard therapy for patients with heart problems, for which treatment is tailored according to the severity of the syndrome and the patient profile. Apart from the clinical seriousness, heart problems is always characterized by an energy depletion status, as indicated by low intramyocardial ATP and coenzyme Q10 levels. We investigated safety and clinical efficacy of Coenzyme Q10 (CoQ10) adjunctive treatment in heart problems which had been diagnosed at least 6 months previously and treated with standard therapy. A total of 2664 patients in NYHA classes II and III were enrolled in this open noncomparative 3-month post marketing study in 173 Italian centers. The daily dosage of CoQ10 was 50-150 mg orally, with the majority of patients (78%) receiving 100 mg/day. Clinical and laboratory parameters were evaluated at the entry into the study and on day 90; the assessment of clinical signs and symptoms was made using from two-to seven-point scales. The results show a low incidence of side effects: 38 adverse effects were reported in 36 patients (1.5%) of which 22 events were considered as correlated to the test treatment. After three months of test treatment the proportions of patients with improvement in clinical signs and symptoms were as follows: cyanosis 78.1%, oedema 78.6%, pulmonary rales 77.8%, enlargement of liver area 49.3%, jugular reflux 71.81%, dyspnoea 52.7%, palpitations 75.4%, sweating 79.8%, subjective arrhytmia 63.4%, insomnia 662.8%, vertigo 73.1% and nocturia 53.6%. Moreover we observed a contemporary improvement of at least three symptoms in 54% of patients; this could be interpreted as an index of improved quality of life.


Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary artery disease.

J Assoc Physicians India; 1994, 42(4):287-9.

Dwivedi S, Agarwal MP.

The effect of bark powder of Terminalia arjuna, an indigenous drug, on anginal frequency, blood pressure, body mass index, blood sugar, cholesterol and HDL-cholesterol was studied in 15 stable (Group A) and 5 unstable (Group B) angina patients before and 3 months after T. arjuna therapy. Tread mill test (TMT) and echocardiographic left ventricular ejection fraction was evaluated in some cases. There was 50% reduction in anginal episodes in Group A cases (P < 0.01). TMT performance improved from moderate to mild changes in 5 patients and one with mild changes became negative for ischemia. The time to the onset of angina and appearance of ST-T changes on TMT after T. arjuna was delayed significantly. However, in patients with unstable angina there was an insignificant reduction in anginal frequency. These patients also needed diltiazem, B-blockers and nitroglycerine in addition to T. arjuna. The drug lowered systolic blood pressure and body mass index to a significant level (p < 0.05) and increased HDL-cholesterol only slightly along with marginal improvement in left ventricular ejection fraction in stable angina patients. There were no deleterious effects on liver or kidney functions. Our results suggest that monotherapy with T. arjuna is fairly effective in patients with symptoms of stable angina pectoris. However, it has a limited role in unstable angina.


Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers.

Indian J Physiol Pharmacol; 1992, 36(4):273-5

Soni KB, Kuttan R.

The effect of curcumin administration in reducing the serum levels of cholesterol and lipid peroxides was studied in ten healthy human volunteers, receiving 500 mg of curcumin per day for 7 days. A significant decrease in the level of serum lipid peroxides (33%), increase in HDL Cholesterol (29%), and a decrease in total serum cholesterol (11.63%) were noted. As curcumin reduced serum lipid peroxides and serum cholesterol, the study of curcumin as a chemopreventive substance against arterial diseases is suggested.

image description
image description